172 related articles for article (PubMed ID: 18815549)
1. Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer.
Yoshitomi H; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Miyazaki M
Pancreas; 2008 Oct; 37(3):275-81. PubMed ID: 18815549
[TBL] [Abstract][Full Text] [Related]
2. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Tachezy M; Reichelt U; Melenberg T; Gebauer F; Izbicki JR; Kaifi JT
Histol Histopathol; 2010 Oct; 25(10):1239-46. PubMed ID: 20712008
[TBL] [Abstract][Full Text] [Related]
4. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
5. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
[TBL] [Abstract][Full Text] [Related]
6. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
[TBL] [Abstract][Full Text] [Related]
7. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
8. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of microvessel density (MVD) in laryngeal squamous cell carcinoma].
Bodnar M; Szylberg Ł; Kaźmierczak W; Marszałek A
Przegl Lek; 2012; 69(10):726-30. PubMed ID: 23421020
[TBL] [Abstract][Full Text] [Related]
10. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
11. Microvessel density assessment in benign and malignant endometrial changes.
Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
[TBL] [Abstract][Full Text] [Related]
12. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma.
Marioni G; Marino F; Giacomelli L; Staffieri C; Mariuzzi ML; Violino E; De Filippis C
Acta Otolaryngol; 2006 Jun; 126(6):633-9. PubMed ID: 16720449
[TBL] [Abstract][Full Text] [Related]
13. High immunohistochemical expression of TGF-β1 predicts a poor prognosis in cervical cancer patients who harbor enriched endoglin microvessel density.
Lin H; Huang CC; Ou YC; Huang EY; Changchien CC; Tseng CW; Fu HC; Wu CH; Li CJ; Ma YY
Int J Gynecol Pathol; 2012 Sep; 31(5):482-9. PubMed ID: 22833091
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
16. Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease-free survival.
Marioni G; Marino F; Blandamura S; D'Alessandro E; Giacomelli L; Guzzardo V; Lionello M; De Filippis C; Staffieri A
Histopathology; 2010 Oct; 57(4):535-43. PubMed ID: 20955379
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.
Martone T; Rosso P; Albera R; Migliaretti G; Fraire F; Pignataro L; Pruneri G; Bellone G; Cortesina G
Oral Oncol; 2005 Feb; 41(2):147-55. PubMed ID: 15695116
[TBL] [Abstract][Full Text] [Related]
19. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
